Verified Insights
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
+91 9425150513 (Asia) support@24lifesciences.com
+91 9425150513 (Asia) support@24lifesciences.com
Download Sample Pdf
MARKET INSIGHTS
The global plaque psoriasis treatment market size was valued at USD 12.4 billion in 2024. The market is projected to grow from USD 13.7 billion in 2025 to USD 21.9 billion by 2032, exhibiting a CAGR of 7.2% during the forecast period.
Plaque psoriasis is a chronic autoimmune condition characterized by raised, red patches covered with silvery-white scales, primarily affecting the skin. It represents approximately 80-90% of all psoriasis cases and often requires long-term treatment management. Current therapeutic approaches include topical therapies, phototherapy, systemic agents, and biologic therapies that target specific immune responses.
The market growth is driven by factors such as increasing psoriasis prevalence (affecting 2-3% of the global population), rising healthcare expenditure, and growing adoption of advanced biologic treatments. While traditional therapies still dominate, biologics like TNF- inhibitors and IL-17/23 inhibitors are gaining traction due to higher efficacy. However, high treatment costs and limited accessibility in developing regions remain key challenges. Recent developments include FDA approvals for novel therapies like deucravacitinib (2022) and continued R&D investments from major pharmaceutical companies.
Increasing Prevalence of Psoriasis Worldwide
The global plaque psoriasis treatment market is driven by the growing disease prevalence, affecting approximately 125 million people worldwide. Rising awareness about psoriasis as a chronic autoimmune disorder has increased demand for effective treatment options. Biologic therapies have shown significant efficacy, with up to 90% of patients achieving 75% improvement in psoriasis area severity index (PASI 75).
Advancements in Biologic Therapies
Pharmaceutical innovation continues to drive market growth, with over 20 biologic drugs currently approved for moderate-to-severe plaque psoriasis. The development of IL-17 and IL-23 inhibitors has revolutionized treatment outcomes, offering superior efficacy compared to traditional systemic therapies. These targeted therapies account for nearly 60% of the biologic psoriasis treatment market.
The global plaque psoriasis treatment market is projected to grow at 9.2% CAGR, reaching $35 billion by 2027
Additionally, the increasing adoption of combination therapies and personalized treatment approaches is expanding treatment options for patients with varying severity levels.
MARKET CHALLENGES
High Cost of Biologic Treatments
Biologic therapies average $50,000-$75,000 annually per patient, creating significant affordability challenges. Many healthcare systems struggle with reimbursement policies, limiting patient access to advanced treatments. Treatment adherence remains problematic due to complex administration regimens and side effects.
Other Challenges
Limited Treatment Efficacy in Severe Cases
Approximately 30% of patients don't achieve adequate response to current biologics, creating unmet needs in treatment-resistant cases. The development pipeline faces challenges in addressing this treatment gap while maintaining safety profiles.
Patent Expirations and Biosimilar Competition
Major biologic drugs face patent expirations through 2025, leading to biosimilar entry that could reduce market value by 15-20%. However, the complex nature of biologics has slowed biosimilar adoption compared to traditional generic drugs. Physician and patient reluctance to switch from reference products continues to moderate biosimilar market penetration.
Emerging Oral Small Molecule Therapies
Novel oral treatments like JAK inhibitors and PDE4 inhibitors present growth opportunities, particularly for patients preferring alternatives to injectables. The oral therapy segment is projected to grow at 12% annually, offering improved convenience and potentially lower costs. Pipeline developments include over 50 novel compounds in various stages of clinical trials targeting new mechanisms of action.
Segment Analysis:| Segment Category | Sub-Segments | Key Insights |
| By Type |
|
Biologic Therapies are emerging as the most innovative segment due to their targeted immune system modulation, offering superior efficacy for moderate-to-severe cases. The development pipeline shows increasing focus on novel biologics with improved safety profiles and longer remission periods compared to traditional systemic agents. |
| By Application |
|
Specialty Dermatology Centers are becoming the preferred treatment setting due to their specialized equipment for phototherapy and biologic infusion capabilities. The increasing trend toward multidisciplinary care models for psoriasis management is driving patient preference for centers offering comprehensive treatment approaches including psychological support. |
| By End User |
|
Adult Population represents the dominant user segment due to the typical onset age of plaque psoriasis. However, treatment approaches are becoming more age-specific, with pediatric formulations gaining attention and geriatric-focused therapies addressing polypharmacy concerns. The adult segment drives most pharmaceutical innovation as companies target working-age patients seeking improved quality of life. |
| By Treatment Approach |
|
Combination Therapy is gaining prominence as physicians increasingly prescribe biologics alongside topical treatments for synergistic effects. The approach addresses both systemic immune dysfunction and localized symptoms, though treatment protocols require careful monitoring. Rotational strategies are also evolving to prevent treatment resistance in chronic patients. |
| By Disease Severity |
|
Moderate-to-Severe Cases represent the key focus area for treatment innovation, particularly where patients experience significant quality-of-life impacts. The severity classification is shifting beyond skin surface area to incorporate psychosocial factors and treatment response history, driving more personalized therapeutic approaches in this segment. |
Biologic Therapies Drive Innovation in Psoriasis Treatment Market
The plaque psoriasis treatment market is dominated by pharmaceutical giants and biotech firms developing advanced biologic therapies. AbbVie leads the market with its blockbuster drug Humira (adalimumab) and newer IL-23 inhibitor Skyrizi (risankizumab), followed closely by Johnson & Johnson through its subsidiary Janssen Biotech with Stelara (ustekinumab) and Tremfya (guselkumab). Novartis has also gained significant market share with its IL-17A inhibitor Cosentyx (secukinumab), becoming one of the fastest-growing biologics for psoriasis treatment.
Several specialized biotechnology companies are making notable contributions in niche segments. Amgen markets Enbrel (etanercept) while collaborating with UCB on newer therapies. Eli Lilly's Taltz (ixekizumab) has shown strong clinical results for moderate-to-severe plaque psoriasis. Emerging players like Dermira (acquired by Eli Lilly) and Galectin Therapeutics are developing novel treatment mechanisms, including topical solutions and small molecule therapies that could challenge existing biologics.
List of Key Plaque Psoriasis Treatment Companies ProfiledAbbvie Inc.
Novartis AG
Eli Lilly and Company
Dermira (Acquired by Eli Lilly)
Allergan (Now part of AbbVie)
Celgene Corporation (Acquired by Bristol-Myers Squibb)
Biogen Inc.
UCB S.A.
Pfizer Inc.
Merck & Co.
The global Plaque Psoriasis Treatment market was valued at $XX million in 2024 and is projected to reach US$XX million by 2031, growing at a CAGR of X% during the forecast period. Biologic therapies account for over 40% of the market share, driven by their superior efficacy in treating moderate-to-severe plaque psoriasis. Major biologics include TNF- inhibitors, IL-17 antagonists, and IL-23 inhibitors, with novel targeted therapies showing promising clinical trial results.
Other TrendsShift Toward Patient-Centric Treatment Approaches
Healthcare providers are increasingly adopting personalized treatment plans, combining biologics with topical therapies for optimized outcomes. Telemedicine adoption for psoriasis management has grown by 65% since 2020, enabling better patient monitoring and therapy adjustment. Insurance coverage expansion for biologics in developed markets has improved treatment accessibility.
Regional Market DevelopmentsNorth America leads with 48% market share due to high treatment adoption rates and favorable reimbursement policies. Asia-Pacific shows the highest growth potential (projected CAGR of 8.2%) with increasing healthcare investments and rising disease awareness. Europe maintains strong growth through biosimilar adoption, with Germany and UK accounting for 35% of regional revenue.
Emerging Therapeutic Innovations
Oral small-molecule inhibitors (JAK/STAT pathway modulators) are gaining traction, offering convenient administration alternatives to injectables. Combination therapies (biologics + phototherapy) show enhanced efficacy in treatment-resistant cases. Digital therapeutics platforms for symptom monitoring and treatment adherence are becoming integral to comprehensive care models.
Market Competition LandscapeKey players like AbbVie (Humira), Johnson & Johnson (Stelara), and Novartis (Cosentyx) maintain 60% combined market share. Emerging biosimilar competition is expected to reduce treatment costs by 25-40% by 2026. Strategic partnerships between biopharma companies and digital health providers are accelerating treatment innovation and patient access programs.
Regional Analysis: Plaque Psoriasis Treatment MarketEurope
Europe represents the second-largest market for plaque psoriasis treatments, characterized by universal healthcare coverage in most countries. The region shows variability in treatment protocols across nations, with Northern Europe demonstrating higher biologic utilization. Price containment policies and health technology assessments influence market access for new therapies. Germany and UK lead in treatment innovation adoption, while Eastern European countries focus on cost-effective options. Increasing biosimilar penetration is reshaping market dynamics across the continent.
Asia-Pacific
Asia-Pacific exhibits the fastest growth in plaque psoriasis treatment market, fueled by improving healthcare infrastructure and rising disease awareness. Japan and Australia dominate the region's advanced therapy adoption, while emerging economies show preference for conventional treatments. Local manufacturers are increasingly developing biosimilars, creating pricing pressure on originator biologics. Cultural perceptions about skin diseases and economic factors continue to influence treatment patterns across diverse markets in the region.
South America
South America's market is growing steadily, with Brazil and Argentina as key contributors. Limited reimbursement for biologics restricts access in several countries, favoring traditional systemics. Increasing number of dermatology specialists and improving diagnostic capabilities support market development. Economic volatility and regulatory complexities pose challenges for market expansion, though local production initiatives are enhancing treatment availability.
Middle East & Africa
The Middle East & Africa region shows varied development, with Gulf countries demonstrating higher treatment sophistication. Wealthier nations have better access to biologics, while Africa largely depends on topical therapies. Cultural stigma associated with skin conditions remains a barrier to treatment in some areas. Increasing medical tourism for psoriasis treatment contributes to regional market dynamics.
This market research report offers a holistic overview of global and regional plaque psoriasis treatment markets for the forecast period 20252032. It presents accurate and actionable insights based on a blend of primary and secondary research.
Market Overview
Global and regional market size (historical & forecast)
Growth trends and value/volume projections
Segmentation Analysis
By product type (topical therapy, phototherapy, systemic agents, biologics)
By application (hospitals, clinics, others)
By distribution channel
Regional Insights
North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country-level data for key markets
Competitive Landscape
Company profiles and market share analysis
Key strategies: M&A, partnerships, expansions
Product portfolio and pricing strategies
Technology & Innovation
Biologic therapies and R&D trends
Novel treatment modalities
Impact of IL-17/23 inhibitors and JAK inhibitors
Market Dynamics
Key drivers supporting market growth
Restraints and potential risk factors
Regulatory trends and challenges
Opportunities & Recommendations
High-growth segments
Investment hotspots
Strategic suggestions for stakeholders
Stakeholder Insights
This report is designed to support strategic decision-making for a wide range of stakeholders, including:
Pharmaceutical and biotech companies
Medical device and diagnostics manufacturers
Healthcare providers and hospital systems
Contract research and manufacturing organizations
Investors, consultants, and policy makers
-> Global plaque psoriasis treatment market was valued at USD 12.4 billion in 2024 and is expected to reach USD 21.9 billion by 2032, growing at a CAGR of 7.2%.
Which key companies operate in Global Plaque Psoriasis Treatment Market?
-> Key players include Johnson & Johnson, Amgen, AbbVie, Eli Lilly, Novartis, Biogen, and Bayer.
-> Key growth drivers include rising psoriasis prevalence (2-3% global population), increasing healthcare expenditure, and adoption of biologic therapies.
-> North America currently leads the market, while Asia-Pacific shows the highest growth potential.
-> Emerging trends include JAK inhibitors, novel IL-17/23 inhibitors, and personalized medicine approaches.
“The data provided by 24LifeScience was clear, well-organized, and useful for internal strategy planning. It helped us understand the competitive landscape more effectively.”
“We used one of their market overview reports for early-stage feasibility work. It gave us a helpful snapshot of current trends and key players in our therapeutic area.”
“I appreciated the team’s responsiveness and willingness to adjust the scope based on our feedback. The final report was aligned with our expectations and timelines.”
“Their custom report on clinical trial trends was a helpful reference as we explored new indications."
“As someone working on early product planning, I found their therapeutic area briefs quite useful. The information was presented in a way that made it easy to extract key takeaways.”
“We didn’t need anything overly complex—just solid, dependable data. 24LifeScience delivered exactly that, without unnecessary fluff.”
“Their reports gave us a good foundation to start our own market assessment. While we supplemented it with other data, this was a great starting point.”
“I’ve used a few of their reports for academic and grant writing purposes. They’re generally well-cited and reliable for understanding market scope.”
At 24LifeScience, we combine domain expertise with dependable research delivery. What truly differentiates us isn't just what we do — it's how we do it. Our clients trust us because we offer consistency, security, value, and most importantly, insight that drives action.
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
We uphold rigorous data validation processes to ensure every report is reliable, up-to-date, and based on credible sources.
24LifeScience powers research for top firms in 20+ nations.Chosen by leading life sciences companies worldwide.
We offer competitive pricing models that align with your project scope — no hidden charges, no lock-in. Tailored pricing for every scale and need.
8–10+ years of life sciences expertise turned into strategic insights.We don’t just summarize data we contextualize it.
Whether it's a ready-made report or a custom project, we deliver within the promised timeline With real-time updates